表紙
市場調査レポート

アレルギー性鼻炎 - パイプラインレビュー

Allergic Rhinitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232791
出版日 ページ情報 英文 197 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
アレルギー性鼻炎 - パイプラインレビュー Allergic Rhinitis - Pipeline Review, H1 2016
出版日: 2016年03月31日 ページ情報: 英文 197 Pages
概要

アレルギー性鼻炎とは、鼻から吸い込んだ物質に対して免疫システムが過剰反応した時に起こるアレルギー反応です。アレルゲンは、アレルギーを引き起こすものを指します。アレルギー性鼻炎の人が花粉、カビ、動物のふけ、またはちりなどのようなアレルゲンを吸い込むと、アレルギー症状を引き起こす化学物質を体が放出します。 症状は、鼻水・鼻づまり、くしゃみ、目が腫れる、口・喉・耳がかゆくなるといったものです。

当レポートでは、アレルギー性鼻炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

アレルギー性鼻炎 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Johnson & Johnson
  • 塩野義製薬
  • GlaxoSmithKline plc
  • Nektar Therapeutics
  • BioTech Tools
  • 第日本住友製薬
  • Novartis AG
  • ALK-Abello A/S
  • 田辺三菱製薬
  • Revance Therapeutics, Inc.
  • Ligand Pharmaceuticals, Inc.
  • 3M Drug Delivery Systems
  • 久光製薬
  • Stallergenes S.A.
  • Allergopharma Joachim Ganzer KG
  • AnaptysBio, Inc.
  • Oxagen Limited
  • Axikin Pharmaceuticals, Inc.
  • Rottapharm SpA
  • Xencor, Inc.
  • ELORAC, Inc.
  • VentiRx Pharmaceuticals, Inc.
  • Laboratorios LETI S.L.
  • Celsus Therapeutics Plc
  • KAEL-GemVax Co., Ltd.
  • GlycoMar Limited
  • Trimel BioPharma SRL
  • Fountain Biopharma Inc.
  • NeoPharm Co., Ltd.
  • Protectimmun GmbH
  • Panmira Pharmaceuticals, LLC.
  • Ziarco Pharma Ltd

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Actair
  • allergenic pollen extract of timothy
  • bepotastine besylate
  • MK-8237
  • Olea Europaea Pollen Extract
  • Depigoid Birch
  • andolast
  • rPhleum
  • AVANZ Olive Immunotherapy for Allergic Rhinitis
  • RT-001
  • OC-459
  • MRX-4
  • rBet v1
  • S-555739
  • Actair
  • Dermatophagoides Pteronyssinus Allergen Extract
  • gpASIT + TM
  • fevipiprant
  • GSK-2245035
  • SUN-0597
  • HP-3060
  • levocabastine hydrochloride
  • (fluticasone furoate + levocabastine hydrochloride)
  • cidoxepin hydrochloride
  • DSP-3025
  • AM-461
  • budesonide
  • AM-211
  • XmAb-7195
  • SUN-0597
  • esketamine
  • NKTR-125
  • tertomotide
  • Drug for Japanese Cedar Pollen Allergy
  • OC-2417
  • TA-270
  • NPB-3
  • ZPL-868087
  • Lactococcus lactis G121
  • Arabinogalactan
  • Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders
  • VTX-378
  • Small Molecules to Inhibit Histamine H3 Receptor for Nasal Congestion and Allergic Rhinitis
  • FB-825
  • GLY-145
  • SUNL-731
  • ANB-020
  • Vaccine for Allergic Rhinitis and Allergic Asthama
  • 854-A
  • Small Molecule for Allergic Rhinitis
  • TBS-6
  • Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders
  • GLY-079
  • rE58
  • Small Molecule to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7703IDB

Summary

Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H1 2016', provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis
  • The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects
  • The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Rhinitis Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Rhinitis - Overview
    • Pipeline Products for Allergic Rhinitis - Comparative Analysis
  • Allergic Rhinitis - Therapeutics under Development by Companies
  • Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes
  • Allergic Rhinitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Allergic Rhinitis - Products under Development by Companies
  • Allergic Rhinitis - Products under Investigation by Universities/Institutes
  • Allergic Rhinitis - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Accolade Pharmaceuticals, LLC
    • Adamis Pharmaceuticals Corporation
    • AFFiRiS AG
    • ALK-Abello A/S
    • Ampio Pharmaceuticals, Inc.
    • AnaptysBio, Inc.
    • ASIT biotech s.a.
    • Axikin Pharmaceuticals, Inc.
    • Chong Kun Dang Pharmaceutical Corp.
    • Chrysalis BioTherapeutics, Inc.
    • ELORAC, Inc.
    • Faes Farma, SA
    • Fountain Biopharma Inc.
    • GenMont Biotech Inc.
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd.
    • HAL Allergy BV
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Hisamitsu Pharmaceutical Co., Inc.
    • J Uriach Y Compania, S.A.
    • Johnson & Johnson
    • Laboratorios LETI S.L.
    • Ligand Pharmaceuticals, Inc.
    • Marinomed Biotechnologie GmbH
    • Merck & Co., Inc.
    • Panmira Pharmaceuticals, LLC.
    • Pfizer Inc.
    • Protectimmun GmbH
    • Regeneron Pharmaceuticals, Inc.
    • RODES Inc.
    • Roxall Medizin GmbH
    • Sanofi
    • Shionogi & Co., Ltd.
    • Stallergenes SAS
    • Taiho Pharmaceutical Co., Ltd.
    • VentiRx Pharmaceuticals, Inc.
    • Xencor, Inc.
    • Ziarco Pharma Ltd
  • Allergic Rhinitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (azelastine hydrochloride + budesonide) - Drug Profile
    • (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile
    • (fluticasone furoate + levocabastine hydrochloride) - Drug Profile
    • (levocabastine hydrochloride + mometasone furoate) - Drug Profile
    • (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile
    • Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
    • Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
    • Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
    • AM-211 - Drug Profile
    • AM-461 - Drug Profile
    • Ampion - Drug Profile
    • ANB-020 - Drug Profile
    • APC-3000 - Drug Profile
    • Arabinogalactan - Drug Profile
    • asapiprant - Drug Profile
    • beta-escin - Drug Profile
    • bilastine - Drug Profile
    • budesonide - Drug Profile
    • CBP-174 - Drug Profile
    • cidoxepin hydrochloride - Drug Profile
    • clustoid wiesenlieschgras - Drug Profile
    • desloratadine - Drug Profile
    • Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases - Drug Profile
    • emedastine difumarate - Drug Profile
    • esketamine hydrochloride - Drug Profile
    • FB-825 - Drug Profile
    • GMNL-32 - Drug Profile
    • gp-ASIT - Drug Profile
    • GSK-2245035 - Drug Profile
    • GSP-301 - Drug Profile
    • Lactococcus lactis G121 - Drug Profile
    • motolimod - Drug Profile
    • nasapaque - Drug Profile
    • pentosan polysulfate sodium - Drug Profile
    • PF-06444752 - Drug Profile
    • PF-06444753 - Drug Profile
    • rE58 - Drug Profile
    • REGN-19081909 - Drug Profile
    • rupatadine - Drug Profile
    • Small Molecule for Allergic Rhinitis - Drug Profile
    • Small Molecule to Agonize TLR-7 and TLR-8 for Oncology, Allergic Rhinitis, Actinic Keratosis and Warts - Drug Profile
    • Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
    • Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile
    • Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile
    • Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders - Drug Profile
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    • STG-120 - Drug Profile
    • TAS-205 - Drug Profile
    • Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile
    • VTX-1463 - Drug Profile
    • XmAb-7195 - Drug Profile
    • Zafi-3 - Drug Profile
    • ZPL-868087 - Drug Profile
  • Allergic Rhinitis - Recent Pipeline Updates
  • Allergic Rhinitis - Dormant Projects
  • Allergic Rhinitis - Discontinued Products
  • Allergic Rhinitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Rhinitis, H1 2016
  • Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H1 2016
  • Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H1 2016
  • Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Allergic Rhinitis - Pipeline by AFFiRiS AG, H1 2016
  • Allergic Rhinitis - Pipeline by ALK-Abello A/S, H1 2016
  • Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by AnaptysBio, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by ASIT biotech s.a., H1 2016
  • Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by ELORAC, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Faes Farma, SA, H1 2016
  • Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H1 2016
  • Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2016
  • Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2016
  • Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016
  • Allergic Rhinitis - Pipeline by J Uriach Y Compania, S.A., H1 2016
  • Allergic Rhinitis - Pipeline by Johnson & Johnson, H1 2016
  • Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H1 2016
  • Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2016
  • Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H1 2016
  • Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Protectimmun GmbH, H1 2016
  • Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by RODES Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H1 2016
  • Allergic Rhinitis - Pipeline by Sanofi, H1 2016
  • Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Allergic Rhinitis - Pipeline by Stallergenes SAS, H1 2016
  • Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Xencor, Inc., H1 2016
  • Allergic Rhinitis - Pipeline by Ziarco Pharma Ltd, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Allergic Rhinitis - Dormant Projects, H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..1), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..2), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..3), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..4), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..5), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..6), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..7), H1 2016
  • Allergic Rhinitis - Dormant Projects (Contd..8), H1 2016
  • Allergic Rhinitis - Discontinued Products, H1 2016
  • Allergic Rhinitis - Discontinued Products (Contd..1), H1 2016
  • Allergic Rhinitis - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Allergic Rhinitis, H1 2016
  • Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top